share_log

Tharimmune | 10-Q: Quarterly report

SEC announcement ·  May 9 20:32
Summary by Futu AI
Tharimmune, a clinical-stage biotechnology company, reported a net loss of $2,256,109 for the quarter ended March 31, 2024, a decrease from the net loss of $2,688,288 for the same period in 2023. The loss per share improved significantly to $(0.19) from $(5.84) year-on-year, reflecting an increase in the weighted average number of common shares outstanding from 460,580 to 11,757,808. Operating expenses for the quarter totaled $2,347,303, down from $2,714,398 in the previous year, with research and development expenses slightly decreasing to $1,025,258 from $1,047,677, and general and administrative expenses reducing to $1,322,045 from $1,666,721. Other income, net of expenses, increased to $91,194 from $26,110, primarily due to a rise in interest income to $95,894 from $32,248. Tharimmune's cash position decreased to $8,427,290 from $10,935,352 at the beginning of the period. The company's business development has been...Show More
Tharimmune, a clinical-stage biotechnology company, reported a net loss of $2,256,109 for the quarter ended March 31, 2024, a decrease from the net loss of $2,688,288 for the same period in 2023. The loss per share improved significantly to $(0.19) from $(5.84) year-on-year, reflecting an increase in the weighted average number of common shares outstanding from 460,580 to 11,757,808. Operating expenses for the quarter totaled $2,347,303, down from $2,714,398 in the previous year, with research and development expenses slightly decreasing to $1,025,258 from $1,047,677, and general and administrative expenses reducing to $1,322,045 from $1,666,721. Other income, net of expenses, increased to $91,194 from $26,110, primarily due to a rise in interest income to $95,894 from $32,248. Tharimmune's cash position decreased to $8,427,290 from $10,935,352 at the beginning of the period. The company's business development has been marked by the FDA's approval of an IND application for TH104, a therapeutic candidate for chronic pruritis in patients with PBC. Tharimmune is also advancing its pipeline with candidates targeting IO targets such as HER2, HER3, and PD-1. The company's future plans include seeking approval for TH104, developing TH103, and progressing TH3215, TH0059, and TH1940 into IND-enabling studies in 2025. Tharimmune has also entered into a patent license agreement with Avior for the development and commercialization of TH104 and TH103.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.